薬剤溶出バルーン(DEB)：グローバル市場分析と予測...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 18
1.2 List of Figures 25
2 Introduction 29
2.1 Catalyst 30
2.2 Related Reports 31
3 Disease Overview 32
3.1 Overview 32
3.1.1 Coronary Artery Disease 32
3.1.2 Peripheral Artery Disease 32
3.2 Anatomy and Physiology 33
3.2.1 Coronary Arteries 33
3.2.2 Peripheral Arteries of the Lower Extremity 34
3.3 Pathophysiology 36
3.3.1 Coronary Artery Disease 36
3.3.2 Peripheral Artery Disease 37
3.4 Clinical Presentation 38
3.4.1 Symptoms 38
3.4.2 Risk Factors 41
3.4.3 Disease Classification 42
3.4.4 Diagnosis 43
3.4.5 Clinical Outcomes 46
3.5 Epidemiology 79
3.5.1 Coronary Artery Disease 79
3.5.2 Peripheral Artery Disease 84
3.6 Economic Impact of Coronary and Peripheral Artery Disease 90
3.6.1 Cost of Coronary Artery Disease 90
3.6.2 Cost of Peripheral Artery Disease 94
3.6.3 Treatment Costs of Coronary and Peripheral Artery Disease 96
4 Competitive Assessment 99
4.1 Overview 99
4.2 Product Profiles by Company 101
4.2.1 Aachen Resonance 102
4.2.2 B. Braun 104
4.2.3 Biotronik 111
4.2.4 Blue Medical 114
4.2.5 Cardionovum 120
4.2.6 C.R. Bard 126
4.2.7 Concept Medical Research 132
4.2.8 Cook Medical 136
4.2.9 Eurocor 138
4.2.10 Medrad (Bayer Healthcare) 153
4.2.11 Medtronic 155
4.2.12 Minvasys 163
5 Unmet Needs 166
5.1 Need for Better Clinical Outcomes in Specific Lesions 166
5.1.1 Chronic Total Occlusions 166
5.1.2 Small-Vessel Coronary Lesions 167
5.1.3 Long Lesions 167
5.1.4 Heavily-Calcified and Uncrossable/Undilatable Lesions 168
5.1.5 Bifurcation Lesions 168
5.2 Need for Better Revascularization of the Femoropopliteal Artery 169
5.3 Difficulty in Treating the Infrapopliteal Artery 171
5.4 Eliminating Mechanisms of Failure with Balloon Angioplasty 172
5.5 Addressing Challenges of Stenting 174
5.5.1 Risk of Post-Procedural Complications 174
5.5.2 In-Stent Restenosis 176
5.5.3 Stent-In-Stent Procedures 177
5.5.4 Prolonged Dual Antiplatelet Therapy 178
5.5.5 Lack of Homogenous Drug Distribution 179
5.5.6 Delayed Healing 179
5.5.7 Stent Fracture 180
5.5.8 Negative Vessel Remodeling 181
5.5.9 Long-Term Vessel Patency 182
5.6 Need for Effective Therapy for Specific Patient Populations 182
5.7 Lack of Clinical Data 183
5.8 Addressing the Complications of Bypass Surgery 183
5.9 Need to Improve Medical Therapy 184
5.10 Comparative Studies on Exercise Therapy for PAD 185
6 Pipeline Products 186
6.1 Overview 186
6.2 Pipeline by Stage of Development 187
6.3 Pipeline Product Profiles 189
6.3.1 NF-κB Decoy Oligo DEB 189
6.3.2 Drug-Coated AngioSculpt 191
6.3.3 BioPath 194
6.3.4 BioStream 195
6.3.5 Boston Scientific Drug-Coated Balloon 196
6.3.6 Coroflex DEBlue 197
6.3.7 Covidien Drug-Coated Balloon 199
6.3.8 Caliber Therapeutics DEB 201
6.3.9 Elixir Medical Corporation DCB 202
6.3.10 LifeTech Scientific Corporation DEB 202
6.3.11 Micell Technologies Drug-Coated Balloon 202
6.3.12 Drug-Coated Chocolate DEB 204
6.3.13 Passeo-18 Lux 206
6.3.14 Vascular Nanotransfer Technologies Drug-Coated Balloon 207
6.3.15 WOMBAT DCB 208
7 Clinical Trial Analysis 210
7.1 Overview 210
7.2 Clinical Trials to Watch 210
7.2.1 Drug-Eluting Balloons 210
7.2.2 Vascular Stents 224
8 Industry Overview 229
8.1 Procedure Trends 229
8.1.1 Factors Contributing to the Rise of Coronary and Peripheral Interventions 229
8.1.2 Coronary Artery Disease 230
8.1.3 Peripheral Artery Disease 235
8.2 Physician Decision-Making Process 243
8.3 Market Access 245
8.3.1 United States 246
8.3.2 European Union 253
8.3.3 Asia-Pacific Region 262
8.3.4 South America 271
8.4 Regulatory Issues/Recalls 275
8.4.1 Regulatory Issues 275
8.4.2 Product Recalls 276
8.5 Mergers and Acquisitions/Partnerships 276
8.5.1 Biosensors International and Eurocor 276
8.5.2 Boston Scientific Corporation and Guidant Corporation 277
8.5.3 Covidien and ev3, CV Ingenuity 277
8.5.4 C.R. Bard and Lutonix 278
8.5.5 Micell Technologies and Maxcor Lifescience 278
8.5.6 Medrad and Bayer 279
8.5.7 Medtronic and Invatec 279
9 Current and Future Players 280
9.1 Overview 280
9.2 Trends in Corporate Strategy 281
9.3 Company Profiles 284
9.3.1 Aachen Resonance 284
9.3.2 AnGes MG 285
9.3.3 AngioScore 287
9.3.4 AVIDAL Vascular 289
9.3.5 B. Braun 291
9.3.6 Biosensors International 293
9.3.7 Biotronik 295
9.3.8 Blue Medical 297
9.3.9 Boston Scientific Corporation 299
9.3.10 Caliber Therapeutics 301
9.3.11 Cardionovum 303
9.3.12 Concept Medical Research 305
9.3.13 Cook Medical 307
9.3.14 Covidien 308
9.3.15 C.R. Bard 310
9.3.16 Elixir Medical Corporation 312
9.3.17 Eurocor 314
9.3.18 LifeTech Scientific Corporation 316
9.3.19 Medtronic 318
9.3.20 Micell Technologies 320
9.3.21 Minvasys 321
9.3.22 TriReme Medical 323
9.3.23 Vascular Nanotransfer Technologies 325
10 Market Drivers, Opportunities, Barriers and Substitutes 327
10.1 Market Drivers 327
10.1.1 Rising Prevalence of Disease 328
10.1.2 Viable Treatment for Select Indications 329
10.1.3 No Metal Left Behind 334
10.1.4 Avoid Stent-in-Stent Procedures 335
10.1.5 Reduce the Need for Prolonged Dual Antiplatelet Therapy 336
10.1.6 Enhanced Vessel Healing and Better Patency 336
10.1.7 Technical Feasibility of Future Interventions 337
10.1.8 DEB as an Adjunctive Therapy 338
10.1.9 Limb Amputation 338
10.1.10 Cost Savings 339
10.1.11 Availability of Long-Term and Cost-Effective Data 340
10.1.12 Launch of DEB in the US 340
10.2 Opportunities 341
10.2.1 Improve DEB Design 341
10.2.2 DEB Hybrid Systems (DEB + Stent) 345
10.2.3 Target Indications Where Stenting is Not Satisfactory 345
10.2.4 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 348
10.2.5 Target Challenging Patient Populations 350
10.2.6 Launch DEB in the Japanese Market 351
10.2.7 Emerging Markets 351
10.3 Market Barriers 352
10.3.1 Slow Adoption 352
10.3.2 High Selling Prices 356
10.3.3 Lack of Reimbursement 357
10.3.4 US FDA Regulatory Challenges 358
10.3.5 Healthcare Cost-Cutting and Reimbursement 359
10.3.6 Availability of Venture Capital 360
10.3.7 Medical Device Excise Tax 361
10.4 Market Substitutes 361
10.4.1 Vascular Stents 361
10.4.2 Liquid Drug Delivery Catheter 365
11 Drug-Eluting Balloon Market Analysis 368
11.1 Global Market Overview 368
11.2 Market Analysis by Type of Disease 369
11.2.1 Coronary Artery Disease 369
11.2.2 Peripheral Artery Disease in the Lower Extremity 370
11.3 Market Distribution by Indication 373
11.4 Primary Versus Adjunctive Therapy 375
11.5 Comparative Market Analysis 377
11.5.1 Coronary Artery Disease 377
11.5.2 Peripheral Artery Disease in the Lower Extremity 379
12 Country Outlooks & Forecasts 381
12.1 Overview 381
12.2 United States 383
12.2.1 Overview 383
12.2.2 Market Analysis 383
12.3 France 386
12.3.1 Overview 386
12.3.2 Market Analysis 386
12.4 Germany 389
12.4.1 Overview 389
12.4.2 Market Analysis 389
12.5 Italy 393
12.5.1 Overview 393
12.5.2 Market Analysis 393
12.6 Spain 396
12.6.1 Overview 396
12.6.2 Market Analysis 396
12.7 United Kingdom 398
12.7.1 Overview 398
12.7.2 Market Analysis 398
12.8 Japan 401
12.8.1 Overview 401
12.8.2 Market Analysis 401
12.9 Brazil 404
12.9.1 Overview 404
12.9.2 Market Analysis 404
12.10 China 406
12.10.1 Overview 406
12.10.2 Market Analysis 406
12.11 India 409
12.11.1 Overview 409
12.11.2 Market Analysis 409
13 Appendix 413
13.1 Bibliography 413
13.2 Abbreviations 445
13.3 Report Methodology 449
13.3.1 Overview 449
13.3.2 Coverage 449
13.3.3 Secondary Research 449
13.3.4 Forecasting Methodology 450
13.4 Physicians and Specialists Included in this Study 452
13.5 Physician Survey 455
13.6 About the Authors 456
13.6.1 Analysts 456
13.6.2 Global Head of Healthcare 457
13.7 About MediPoint 458
13.8 About GlobalData 458
13.9 Disclaimer 458